FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment
 

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

More...